Abstract:

AIM: To evaluate the efficacy and safety of recombinant human interferon alfa2b oxygen inbreathe for bronchiolitis. METHODS: Eighty-six children with bronchiolitis were divided into control group and observation group, with 43 cases in each group. The two groups were generally treated in the same way, while the observation group was additionally inhaled with recombinant human interferon alfa2b oxygen drive. At end of the treatment period, the total effective rate, clinical symptoms and signs, hospital stay, adverse reactions, and blood routine and biochemical indexes were observed and compared between the two groups. RESULTS: The total effective rate (95.35%) of the observation group was significantly higher than that of the control group (83.72%) (P<0.05); the duration of clinical symptoms and signs of the treatment group was less than those of the control group (P<0.05); There was no significant difference between the two groups of children in the blood routine, blood biochemical indicators and regarding adverse reactions (P>0.05). CONCLUSION: Recombinant human interferon α2b oxygen inbreathe can improve the clinical cure rate, shorten the hospital stay of bronchiolitis with safety.

Key words: recombinant human interferon α2b, the nebulizations of oxygen inbreathe, bronchiolitis, efficacy